| Literature DB >> 32130916 |
Ingrid E Frohner1, Ingrid Mudrak1, Stefan Schüchner1, Dorothea Anrather2, Markus Hartl2, Jean-Marie Sontag3, Estelle Sontag3, Brian E Wadzinski4, Teresa Preglej5, Wilfried Ellmeier5, Egon Ogris6.
Abstract
Protein phosphatase 2A (PP2A) is an important regulator of signal transduction pathways and a tumor suppressor. Phosphorylation of the PP2A catalytic subunit (PP2AC) at tyrosine 307 has been claimed to inactivate PP2A and was examined in more than 180 studies using commercial antibodies, but this modification was never identified using mass spectrometry. Here we show that the most cited pTyr307 monoclonal antibodies, E155 and F-8, are not specific for phosphorylated Tyr307 but instead are hampered by PP2AC methylation at leucine 309 or phosphorylation at threonine 304. Other pTyr307 antibodies are sensitive to PP2AC methylation as well, and some cross-react with pTyr residues in general, including phosphorylated hemagglutinin tags. We identify pTyr307 using targeted mass spectrometry after transient overexpression of PP2AC and Src kinase. Yet under such conditions, none of the tested antibodies show exclusive pTyr307 specificity. Thus, data generated using these antibodies need to be revisited, and the mechanism of PP2A inactivation needs to be redefined.Entities:
Keywords: Abcam monoclonal E155; PP2A catalytic subunit; PP2A inactivation; PP2A phospho-tyrosine 307; PP2A tumor suppressor; SCBT monoclonal F-8; methyl-PP2A sensitivity; non-specific antibody
Mesh:
Substances:
Year: 2020 PMID: 32130916 DOI: 10.1016/j.celrep.2020.02.035
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423